Trevena (TRVN)
(Delayed Data from NSDQ)
$0.39 USD
-0.01 (-3.55%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $0.41 +0.02 (6.38%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Trevena, Inc. [TRVN]
Reports for Purchase
Showing records 61 - 80 ( 114 total )
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List-Updates
Provider: WEDBUSH SECURITIES INC.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Oliceridine''s Phase 3 Trials, APOLLO-1 - APOLLO-2, Are Enrolled; Data Q1
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Best Ideas List for 2017This report contains brief updates on the following: ARDX, BC, BLDR, CVA, FINL, FIS, IPG, LULU, LXRX, MASI, NRZ, PFPT, PB, PHM, QUOT, SHAK, TRVN, ZNGA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: LURIA G
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Focus on Oliceridine Ahead of Phase III Data in 1Q17; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Models Adjusted Post 3Q''16 Results; Catalyst Expected in 1Q?17
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Trevena Reports 3Q16 as We Head Towards Oliceridine Phase III Data in 1Q17; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts from ASA, Oliceridine Has Potential to Shift the Paradigm; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
KOL?s Address the Need for Oliceridine at ASA Meeting
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Ended Q2 With Strong Balance Sheet, As APOLLO Trials Are Enrolling
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Oliceridine After Management Meetings and 2Q16 Earnings; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
TRV027 Failure Puts Focus Back on Oliceridine; Reiterate OUTPERFORM and Adjust Our PT to $16
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.